Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists.

VERTIS CV later confirmed cardiovascular safety for ertugliflozin, with neutrality for three-point major adverse CV events, fewer hospitalizations for HF, and a renal signal that did not reach statistical significance for superiority [ 52 ].

also in 111,027 other papers